Figure 1.

TTP RNA is a biomarker for BCR risk assessment. A, Box-and-whisker plots of multiple prostate cancer patient cohorts (Taylor et al., Das et al., Ross et al., Karnes et al., and Klein et al.) showing TTP RNA expression at prostatectomy in prostate tumors that remained indolent (No BCR) versus tumors that developed BCR (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-sided Mann-Whitney U test). B, C, and D, Kaplan-Meier curves showing the time to BCR in primary prostate cancer patients separated into TTP-High and TTP-Low subtypes based on median TTP RNA levels for pathologically low-grade patients in the Taylor et al. cohort (B), all patients in the Das et al. cohort (C), and pathologically low-grade patients in the Das et al. cohort (D) (p-values, Mantel-Cox log-rank test).